(NASDAQ: BBNX) Beta Bionics's forecast annual revenue growth rate of 41.31% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 9.65%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.43%.
Beta Bionics's revenue in 2026 is $88,570,000.On average, 12 Wall Street analysts forecast BBNX's revenue for 2026 to be $5,949,928,880, with the lowest BBNX revenue forecast at $5,341,508,479, and the highest BBNX revenue forecast at $6,655,643,715. On average, 11 Wall Street analysts forecast BBNX's revenue for 2027 to be $7,885,251,658, with the lowest BBNX revenue forecast at $6,527,532,038, and the highest BBNX revenue forecast at $9,271,147,042.
In 2028, BBNX is forecast to generate $11,380,367,114 in revenue, with the lowest revenue forecast at $9,966,295,966 and the highest revenue forecast at $12,943,241,514.